Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and South America.

about

Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and South America.

Item

http://www.wikidata.org/entity/Q52661543

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Durability of Efavirenz Compar ...... and Central and South America.

@en

Durability of Efavirenz Compar ...... and Central and South America.

@nl

type

Item

label

Durability of Efavirenz Compar ...... and Central and South America.

@en

Durability of Efavirenz Compar ...... and Central and South America.

@nl

prefLabel

Durability of Efavirenz Compar ...... and Central and South America.

@en

Durability of Efavirenz Compar ...... and Central and South America.

@nl

P1476

Durability of Efavirenz Compar ...... and Central and South America.

@en

P2093

Brenda E Crabtree-Ramírez

http://www.w3.org/2001/XMLSchema#string

Bryan E Shepherd

http://www.w3.org/2001/XMLSchema#string

Eduardo Gotuzzo

http://www.w3.org/2001/XMLSchema#string

Juan G Sierra-Madero

http://www.w3.org/2001/XMLSchema#string

Marcelo Wolff

http://www.w3.org/2001/XMLSchema#string

Yanink Caro-Vega

http://www.w3.org/2001/XMLSchema#string

P2860

Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America.

Cross-sectional analysis of late HAART initiation in Latin America and the Caribbean: late testers and late presenters.

Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease

Use of third line antiretroviral therapy in Latin America

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.

A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States.

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.

P304

ofy004

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/OFID/OFY004

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pablo F Belaunzarán-Zamudio

P577

2018-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29527539

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

5836274

http://www.w3.org/2001/XMLSchema#string